Bingbing Li

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin et al. · The Lancet Neurology · 2014 · 815 citations

Disease Management, Relapsing-remitting Multiple Sclerosis, Disease Progression +7

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Jeffrey Cohen et al. · New England Journal of Medicine · 2020 · 650 citations · Full text

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Fred Lublin, David H. Miller, Mark S. Freedman et al. · The Lancet · 2016 · 445 citations · Full text

Oral Fingolimod, Neurological Disorder, Clinical Neurology +9

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

Jutta Gärtner, Stephen L. Hauser, Amit Bar‐Or et al. · Multiple Sclerosis Journal · 2022 · 89 citations · Full text

Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota

Ruiting Han, Huihui Qiu, Jing Zhong et al. · Phytomedicine · 2021 · 54 citations

Metabolic Syndrome, Si Miao Formula, Hepatology +13